Unlock instant, AI-driven research and patent intelligence for your innovation.

Multi-specific proteins

A protein-specific technology, applied in the field of multi-specific proteins

Pending Publication Date: 2022-03-18
MOLECULAR PARTNERS AG
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the same antibody given in another trial (NCT00612664) caused grade 4 hepatitis, which led to the termination of the trial (Simeone E. and Ascierto P.A., 2012, J. Immunotoxicology, Vol. 9, pp. 241-247)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multi-specific proteins
  • Multi-specific proteins
  • Multi-specific proteins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0308] Example 1 - Design of Multispecific Binding Proteins

[0309] Generation of various forms of multispecific binding proteins (see Figure 5A and Figure 5B ), and their ability to enhance NF-κB activation in h4-1BB-HT1080 reporter cells was assessed.

[0310] NF-κB reporter cells (h4-1BB-HT1080) transfected with human 4-1BB were used to assess the presence of the FAP binding domain shown in SEQ ID NO: 2 and SEQ ID NO: 2 in the presence of CHO cells expressing human FAP. Functional activity of various multispecific binding proteins from one to three 4-1BB binding domains shown in 3.

[0311] In vitro NF-κB activation assay in the presence of CHO cells expressing human FAP: HT1080 human fibrosarcoma cells were stably transfected with cDNA encoding full-length human 4-1BB and the pNIFTY-Lucia NF-κB reporter gene as follows . In the same manner, CHO cells were stably transfected with cDNA encoding human FAP. Using a 96-well plate, plate 40,000 h4-1BB-HT1080 reporter c...

Embodiment 2

[0314] Example 2 - Binding affinity of multispecific molecules

[0315] The following examples describe experiments performed to determine the species cross-reactivity of different domains in the multispecific binding protein A (MpA) comprising SEQ ID NO:6. The interaction of MpA with serum albumin, 4-1BB and FAP was analyzed for three species (human, cynomolgus monkey and mouse).

[0316] Materials and methods

[0317] ProteOn setup for binding of MpA to 4-1BB of different species: SPR measurements were performed using a ProteOn XPR36 instrument (BioRad). The running buffer contains PBS pH7.4 (PBST). bio.h4-1BB, bio.c4-1BB and bio.m4-1BB were immobilized on NLC chips (BioRad) to a level of 320RU. Binding of MpA to 4-1BB was measured by injecting MpA at serial dilutions of 30 nM, 10 nM, 3.3 nM, 1.1 nM and 0.3 nM with 180 s of association and 1800 s of dissociation using a constant flow rate of 100 μl / min (see table 3). Measurements were repeated three times and 10 m...

Embodiment 3

[0338] Example 3 - Analysis of Simultaneous Binding of MpA to 4-1BB, FAP and Human Serum Albumin by Surface Plasmon Resonance combine

[0339] The following experiment describes the performance of a surface plasmon resonance experiment analyzing the simultaneous binding of a multispecific binding protein A (MpA) comprising SEQ ID NO: 6 to human 4-1BB, human FAP and human serum albumin, respectively.

[0340] The analysis was performed using the following setup: Biotinylated human 4-1BB was immobilized on the surface of a neutralizing avidin-coated NLC chip before starting the binding measurements. In the first step, MpA is added, which has a slow off-rate of 4-1BB. Second, hFAP was applied as a secondary target, and then HSA was added as a tertiary and final target.

[0341] SPR measurements were performed using a ProteOn XPR36 instrument (BioRad). PBS pH 7.4 containing 0.005% Tween 20 was used as running buffer. 360 RU of 1OnM biotinylated human 4-1BB (bio.h4-1BB-Fc) w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
dissociationaaaaaaaaaa
affinityaaaaaaaaaa
Login to View More

Abstract

The present disclosure relates to multispecific recombinant proteins useful in the treatment of cancer.

Description

[0001] Cross references to related patent applications [0002] This application claims the benefit of priority to U.S. Provisional Application 62 / 857,037, filed June 4, 2019, the disclosure of which is incorporated herein by reference in its entirety. technical field [0003] The present invention relates to multispecific proteins useful in the treatment of cancer. [0004] Incorporated by reference into the sequence listing [0005] The computer-readable nucleotide / amino acid sequence listing submitted at the same time is incorporated by reference in its entirety and identified as follows: ASCII (text) file named 53893A_Seqlisting.txt; size: 107,894 bytes, created May 2020 21st. Background technique [0006] Several members of the tumor necrosis factor receptor (TNFR) family function after initial T cell activation to sustain T cell responses and thus have critical roles in the organization and function of the immune system. CD27, 4-1BB (CD137), OX40 (CD134), HVEM, CD3...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/46C12N15/13C12P21/02A61K39/395A61P35/00
CPCC07K16/28C07K16/2878C07K16/18A61P35/00C07K2317/31C07K2317/92C07K2317/51A61K2039/505C07K14/435C07K16/40C07K2317/94A61K38/00C07K14/70578C07K14/765C07K2319/70
Inventor C·雷琴A·林克J·赫普V·列维茨基
Owner MOLECULAR PARTNERS AG